{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:50:00Z","timestamp":1773435000892,"version":"3.50.1"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"European Union 7th Framework Programme for Research and Technological Development","award":["HEALTH-F7-305507 HOMAGE (EU FP7 305507"],"award-info":[{"award-number":["HEALTH-F7-305507 HOMAGE (EU FP7 305507"]}]},{"DOI":"10.13039\/501100001665","name":"French National Research Agency","doi-asserted-by":"crossref","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"crossref"}]},{"name":"French PIA project \u2018Lorraine Universit\u00e9 d\u2019Excellence\u2019","award":["ANR-15-IDEX-04-LUE"],"award-info":[{"award-number":["ANR-15-IDEX-04-LUE"]}]},{"name":"Contrat de Plan Etat Lorraine IT2MP and FEDER Lorraine"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,2,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Uncontrolled blood pressure (BP) increases the risk of developing heart failure (HF). The effect of spironolactone on BP of patients at risk of developing HF is yet to be determined. To evaluate the effect of spironolactone on the BP of patients at risk for HF and whether renin can predict spironolactone\u2019s effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>HOMAGE (Heart OMics in Aging) was a prospective multicentre randomized open-label blinded endpoint (PROBE) trial including 527 patients at risk for developing HF randomly assigned to either spironolactone (25\u201350 mg\/day) or usual care alone for a maximum of 9\u2009months. Sitting BP was assessed at baseline, Months 1 and 9 (or last visit). Analysis of covariance (ANCOVA), mixed effects models, and structural modelling equations was used. The median (percentile25\u201375) age was 73 (69\u201379) years, 26% were female, and &amp;gt;75% had history of hypertension. Overall, the baseline BP was 142\/78\u2009mmHg. Patients with higher BP were older, more likely to have diabetes and less likely to have coronary artery disease, had greater left ventricular mass (LVM), and left atrial volume (LAV). Compared with usual care, by last visit, spironolactone changed SBP by \u221210.3 (\u221213.0 to \u22127.5) mmHg and DBP by \u22123.2 (\u22124.8 to \u22121.7) mmHg (P\u2009&amp;lt;\u20090.001 for both). A higher proportion of patients on spironolactone had controlled BP &amp;lt;130\/80\u2009mmHg (36 vs. 26%; P\u2009=\u20090.014). Lower baseline renin levels predicted a greater response to spironolactone (interactionP = 0.041).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Spironolactone had a clinically important BP-lowering effect. Spironolactone should be considered for lowering blood pressure in patients who are at risk of developing HF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvab031","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T19:24:26Z","timestamp":1617305066000},"page":"149-156","source":"Crossref","is-referenced-by-count":14,"title":["Spironolactone effect on the blood pressure of patients at risk of developing heart failure: an analysis from the HOMAGE trial"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2304-6138","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferreira","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d'Investigation Clinique Plurith\u00e9matique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, 4 rue du Morvan, 54500 Nancy, France"}]},{"given":"Timothy","family":"Collier","sequence":"additional","affiliation":[{"name":"Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, UK"}]},{"given":"Andrew L","family":"Clark","sequence":"additional","affiliation":[{"name":"Department of Academic Cardiology, University of Hull, Daisy Building, Castle Hill Hospital, Castle Road, Cottingham, UK"}]},{"given":"Mamas A","family":"Mamas","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Oxford Road, Manchester & Keele Cardiovascular Research Group, Keele University, Keele, UK"}]},{"given":"Hans-Peter Brunner-La","family":"Rocca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands"}]},{"given":"Stephane","family":"Heymans","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-6528","authenticated-orcid":false,"given":"Arantxa","family":"Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Program of Cardiovascular Diseases, CIMA Universidad de Navarra and IdiSNA, Pamplona, Spain; CIBERCV, Carlos III Institute of Health, Madrid, Spain"}]},{"given":"Fozia Z","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Oxford Road, Manchester & Keele Cardiovascular Research Group, Keele University, Keele, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3116-9450","authenticated-orcid":false,"given":"Johannes","family":"Petutschnigg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charit\u00e9 University Medicine Berlin, and German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5831-0800","authenticated-orcid":false,"given":"Blerim","family":"Mujaj","sequence":"additional","affiliation":[{"name":"Department of Diagnostic and Interventional Radiology, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany"}]},{"given":"Joe","family":"Cuthbert","sequence":"additional","affiliation":[{"name":"Department of Academic Cardiology, University of Hull, Daisy Building, Castle Hill Hospital, Castle Road, Cottingham, UK"}]},{"given":"Philippe","family":"Rouet","sequence":"additional","affiliation":[{"name":"Institut de M\u00e9decine Mol\u00e9culaire de Rangueil, UMR INSERM, Toulouse 1048, France"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7175-0464","authenticated-orcid":false,"given":"Pierpaolo","family":"Pellicori","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK"}]},{"given":"Beatrice","family":"Mariottoni","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cortona Hospital, Arezzo, Italy"}]},{"given":"Franco","family":"Cosmi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cortona Hospital, Arezzo, Italy"}]},{"given":"Frank","family":"Edelmann","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Cardiology, Campus Virchow Klinikum, Charit\u00e9 University Medicine Berlin, and German Centre for Cardiovascular Research (DZHK), Partner Site Berlin, Germany"}]},{"given":"Lutgarde","family":"Thijs","sequence":"additional","affiliation":[{"name":"Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium"}]},{"given":"Jan A","family":"Staessen","sequence":"additional","affiliation":[{"name":"Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2151-7178","authenticated-orcid":false,"given":"Mark","family":"Hazebroek","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5549-1298","authenticated-orcid":false,"given":"Job","family":"Verdonschot","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Maastricht University Medical Center, Maastricht, The Netherlands"}]},{"given":"Patrick","family":"Rossignol","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d'Investigation Clinique Plurith\u00e9matique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, 4 rue du Morvan, 54500 Nancy, France"}]},{"given":"Nicolas","family":"Girerd","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d'Investigation Clinique Plurith\u00e9matique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, 4 rue du Morvan, 54500 Nancy, France"}]},{"given":"John G","family":"Cleland","sequence":"additional","affiliation":[{"name":"Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow Royal Infirmary, Glasgow, UK"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Lorraine, Inserm, Centre d'Investigation Clinique Plurith\u00e9matique 1433, U1116, CHRU de Nancy, F-CRIN INI-CRCT, 4 rue du Morvan, 54500 Nancy, France"}]}],"member":"286","published-online":{"date-parts":[[2021,4,2]]},"reference":[{"key":"2022030710594893600_pvab031-B1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(05)17741-1","article-title":"Global burden of hypertension: analysis of worldwide data","volume":"365","author":"Kearney","year":"2005","journal-title":"Lancet"},{"key":"2022030710594893600_pvab031-B2","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJMoa003417","article-title":"Impact of high-normal blood pressure on the risk of cardiovascular disease","volume":"345","author":"Vasan","year":"2001","journal-title":"N Engl J Med"},{"key":"2022030710594893600_pvab031-B3","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0000000000000848","article-title":"Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure\u2013meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"2022030710594893600_pvab031-B4","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"key":"2022030710594893600_pvab031-B5","first-page":"e426","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"138","author":"Whelton","year":"2018","journal-title":"Circulation"},{"key":"2022030710594893600_pvab031-B6","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","article-title":"2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension","volume":"36","author":"Williams","year":"2018","journal-title":"J Hypertens"},{"key":"2022030710594893600_pvab031-B7","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","article-title":"Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial","volume":"386","author":"Williams","year":"2015","journal-title":"Lancet"},{"key":"2022030710594893600_pvab031-B8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/eurheartj\/ehaa758","article-title":"The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart \u2018OMics\u2019 in AGEing (HOMAGE) randomized clinical trial","volume":"42","author":"Cleland","year":"2020","journal-title":"Eur Heart J"},{"key":"2022030710594893600_pvab031-B9","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1002\/ejhf.1716","article-title":"Effects of spironolactone on serum markers of fibrosis in people at high risk of developing heart failure: rationale, design and baseline characteristics of a proof-of-concept, randomised, precision-medicine, prevention trial. The Heart OMics in AGing (HOMAGE) trial","volume":"22","author":"Pellicori","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022030710594893600_pvab031-B10","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1161\/01.HYP.10.4.404","article-title":"Renin suppression by saline is blunted in nonmodulating essential hypertension","volume":"10","author":"Rabinowe","year":"1987","journal-title":"Hypertension"},{"key":"2022030710594893600_pvab031-B11","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.050896","article-title":"The association of serum aldosterone and plasma renin activity with ambulatory blood pressure in African Americans: the Jackson Heart Study","author":"Joseph","year":"2021","journal-title":"Circulation"},{"key":"2022030710594893600_pvab031-B12","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1210\/jc.2016-3867","article-title":"Renin phenotypes characterize vascular disease, autonomous aldosteronism, and mineralocorticoid receptor activity","volume":"102","author":"Hundemer","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2022030710594893600_pvab031-B13","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/L18-0027","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension","volume":"168","author":"Brown","year":"2018","journal-title":"Ann Intern Med"},{"key":"2022030710594893600_pvab031-B14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/hr.2010.236","article-title":"Aldosterone-to-renin ratio and home blood pressure in subjects with higher and lower sodium intake: the Ohasama study","volume":"34","author":"Satoh","year":"2011","journal-title":"Hypertens Res"},{"key":"2022030710594893600_pvab031-B15","doi-asserted-by":"crossref","first-page":"ii127","DOI":"10.1161\/01.HYP.8.6_Pt_2.II127","article-title":"Definitions and characteristics of sodium sensitivity and blood pressure resistance","volume":"8","author":"Weinberger","year":"1986","journal-title":"Hypertension"},{"key":"2022030710594893600_pvab031-B16","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2022030710594893600_pvab031-B17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2022030710594893600_pvab031-B18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1093\/ajh\/hpx210","article-title":"Spironolactone and resistant hypertension in heart failure with preserved ejection fraction","volume":"31","author":"Rossignol","year":"2018","journal-title":"Am J Hypertens"},{"key":"2022030710594893600_pvab031-B19","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/ejhf.1909","article-title":"Spironolactone dose in heart failure with preserved ejection fraction: findings from TOPCAT","volume":"22","author":"Ferreira","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2022030710594893600_pvab031-B20","doi-asserted-by":"crossref","first-page":"12a","DOI":"10.1016\/0002-9149(93)90239-9","article-title":"Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension","volume":"71","author":"Brilla","year":"1993","journal-title":"Am J Cardiol"},{"key":"2022030710594893600_pvab031-B21","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jchf.2020.11.010","article-title":"Proteomic and mechanistic analysis of spironolactone in patients at risk for HF","volume":"9","author":"Ferreira","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2022030710594893600_pvab031-B22","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1136\/heartjnl-2018-313182","article-title":"Potential spironolactone effects on collagen metabolism biomarkers in patients with uncontrolled blood pressure","volume":"105","author":"Ferreira","year":"2019","journal-title":"Heart"},{"key":"2022030710594893600_pvab031-B23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.116.005156","article-title":"Association between left atrial dilatation and invasive hemodynamics at rest and during exercise in asymptomatic aortic stenosis","volume":"9","author":"Christensen","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2022030710594893600_pvab031-B24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/HYPERTENSIONAHA.116.08567","article-title":"Clinic versus daytime ambulatory blood pressure difference in hypertensive patients: the impact of age and clinic blood pressure","volume":"69","author":"Banegas","year":"2017","journal-title":"Hypertension"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvab031\/37767335\/pvab031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/2\/149\/42750766\/pvab031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/8\/2\/149\/42750766\/pvab031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,7]],"date-time":"2022-03-07T11:02:35Z","timestamp":1646650955000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/8\/2\/149\/6208891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,2]]},"references-count":24,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,4,2]]},"published-print":{"date-parts":[[2022,2,16]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvab031","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,3]]},"published":{"date-parts":[[2021,4,2]]}}}